Tech Company Financing Transactions
Quartet Medicine Funding Round
Quartet Medicine secured a $6.3 million Series A funding round on 10/7/2015. Backers included Remeditex Ventures and private investors.
Transaction Overview
Company Name
Announced On
10/7/2015
Transaction Type
Venture Equity
Amount
$6,250,000
Round
Series A
Investors
Remeditex Ventures (John Creecy)
Proceeds Purpose
Quartet plans to use the funding to advance its lead program focused on modulating tetrahydrobiopterin (BH4) through early clinical testing over the next two years.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 10th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Quartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerhard Koenig
Browse more venture capital transactions:
Prev: 10/7/2015: Binary Fountain venture capital transaction
Next: 10/7/2015: Spreedly venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs